Inositol for PMOS: What You Need to Know

If you’ve been navigating irregular cycles, hormonal symptoms, or the challenges of trying to conceive, you’re not alone. Many women dealing with what was long known as polycystic ovary syndrome (PCOS) have spent years searching for answers that actually make sense for their bodies.

You may increasingly hear the term polyendocrine metabolic ovarian syndrome (PMOS) used when discussing the condition traditionally known as polycystic ovary syndrome (PCOS). The terminology aims to better reflect the broader hormonal and metabolic features of the condition. Whatever name is used, the day-to-day realities remain the same: insulin resistance, disrupted ovulation, elevated androgens, and the emotional weight that often comes with it.

One nutrient that continues to stand out in research for women with PMOS is inositol. Here’s what you need to know.

What is Inositol?

Inositol is a naturally occurring sugar alcohol that plays an important role in cell signalling, particularly in pathways that involve insulin and follicle stimulating hormone (FSH). The two forms most studied in women’s health are myo-inositol and D-chiro-inositol.

Myo-inositol is the predominant form found in the body and is especially relevant for ovarian function and insulin sensitivity. D-chiro-inositol is present in smaller amounts and is involved in different aspects of insulin signalling.

Why Inositol Matters in PMOS

Insulin resistance is a common feature of PMOS and can occur even in women who are not overweight. High insulin levels drive increased androgen production, disrupt ovulation, and contribute to many of the symptoms associated with the condition.

Because inositol supports insulin signalling at a cellular level, researchers have investigated whether supplementation can help improve hormonal balance, restore more regular ovulation, and support fertility outcomes.

What the Research Shows

Several systematic reviews and meta-analyses of randomised controlled trials have examined inositol in women with the condition formerly known as PCOS (now PMOS).

Key findings include:

• Improved insulin sensitivity (lower HOMA-IR and fasting insulin)
• Reductions in total and free testosterone
• Increases in sex hormone binding globulin (SHBG)
• Higher rates of ovulation in some studies
• Potential improvements in menstrual regularity

A 2026 umbrella review of meta-analyses found evidence that inositol may improve several hormonal and metabolic markers compared with placebo or folic acid alone, with potential benefits for ovulation and live birth rates reported in some analyses. Myo-inositol (often combined with folic acid) generally performed more consistently than D-chiro-inositol alone for reproductive outcomes.

Other meta-analyses have shown that myo-inositol may improve the quality of oocytes and embryos in women undergoing assisted reproduction, although results on clinical pregnancy and live birth rates remain mixed and more high-quality data are still needed.

Importantly, inositol is generally well tolerated. Gastrointestinal side effects are typically milder than those commonly reported with metformin.

Myo-Inositol vs D-Chiro-Inositol

Most of the stronger evidence for fertility and cycle regulation centres on myo-inositol. High doses of D-chiro-inositol alone have raised some theoretical concerns about ovarian function in certain contexts, which is why many clinicians prefer formulations that are primarily myo-inositol or that use a carefully considered ratio. 

Some supplements combine myo-inositol and D-chiro-inositol in a 40:1 ratio. However, current international guidance does not recommend one specific inositol type, dose or combination due to insufficient high-quality evidence.

Current international guidance notes that inositol (in any form) can be considered based on individual preference, acknowledging limited potential for harm and possible metabolic and menstrual benefits, while recognising that evidence for some clinical outcomes is still developing.

Practical Considerations

If you are exploring inositol as part of your PMOS management:

• Consistency matters. Benefits are usually assessed after several weeks to a few months of daily use.
• Quality and dose vary between products. Look for transparent labelling.
• Inositol is a supplement, not a medication. It should complement, not replace, medical advice and prescribed treatments.
• Many women use it alongside lifestyle approaches that also support insulin sensitivity (nutrition, movement, sleep, and stress management).

At SoFitt.™ Nutrition, we focus on evidence informed nutritional support for women navigating fertility and hormonal health. SoFitt.™ Nutrition's Advanced Fertility Support Shake contains both myo-inositol and D-chiro-inositol in a carefully formulated 40:1 ratio, alongside other nutrients selected to support female fertility and reproductive health.

Final Thoughts

Inositol is one of the better researched nutritional options for women with PMOS, particularly those dealing with insulin resistance, irregular cycles, or fertility challenges. While it is not a cure and results vary between individuals, the body of evidence continues to grow and many women find it a helpful part of their overall approach.

As always, speak with your healthcare provider or a fertility nutrition specialist before starting any new supplement, especially if you are trying to conceive or undergoing fertility treatment. Personalised guidance remains the most reliable path.

With the right information, professional support and evidence-informed nutrition, you can make informed choices about supporting your hormonal and reproductive health.

References

• Duan M, Yang M, Li C, Wu X, Yin X, Zhu H. Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. Frontiers in Endocrinology. 2026;17:1741509. https://doi.org/10.3389/fendo.2026.1741509
• Fitz V, Graca S, Mahalingaiah S, et al. Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. The Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630-1655. https://doi.org/10.1210/clinem/dgad762
• Akbari Sene A, et al. The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: a systematic review and meta-analysis of randomized clinical trial studies. International Journal of Reproductive BioMedicine. 2025;23(5):353-376. https://doi.org/10.18502/ijrm.v23i5.19260
• Showell MG, Mackenzie-Proctor R, Jordan V, Hart RJ. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2018;12:CD012378. https://doi.org/10.1002/14651858.CD012378.pub2